TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03610672

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: OD prevention/response training
Description: Participants will view a 13-minute OD prevention and response training video (available online free-of-charge). This video covers NY State's recommended curriculum for Overdose Prevention: how to prevent, identify, and respond to an OD, including information on the factors that could heighten risk for overdose (mixing drugs, changes in tolerance and drug purity, and using alone), how to respond to an overdose (rescue breathing, calling 911), and specific instructions on how and when to administer naloxone to someone who is overdosing. After the video, research staff will review key information, answer any questions participants may have, demonstrate assembly of the intranasal naloxone atomizer and ensure participants are able to assemble it. A prescription for naloxone, as well as a standard naloxone kit containing two doses of the medication and atomizers for intranasal administration, will be given to participants, along with printed literature reviewing key training information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OD prevention/response training + PI mobile application
Description: Participants will receive the same OD intervention as those in the first arm, as well as receiving mobile phones pre-loaded with the PI App. This intervention includes daily prompts plus key components of evidence-based cognitive behavioral interventions, including Functional Analysis of Drug Use, Self-Management, and Social/Recreational Counseling and additional content on Distress Tolerance, the relationship between Peer Networks and Drug Use, and pertinent resources.
Study: NCT05770960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxegol
Description: Oral administration of Naloxegol after waking up from the Midazolam administration during the colonoscopy.

Intervention type: DRUG
Group type: OTHER
Intervention: Naloxegol
Description: Oral administration of Naloxegol after waking up from the Midazolam administration during the colonoscopy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: codeine phosphate
Description: Oral administration of Codeine after waking up from the Midazolam administration during the colonoscopy.

Intervention type: DRUG
Group type: OTHER
Intervention: codeine phosphate
Description: Oral administration of Codeine after waking up from the Midazolam administration during the colonoscopy.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Oral administration of siripus simplex syrup after waking up from the Midazolam administration during the colonoscopy.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Oral administration of siripus simplex syrup after waking up from the Midazolam administration during the colonoscopy.
Study: NCT01601522

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peanut protein
Description: 500 mg

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peanut protein
Description: 500 mg

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Oat flour
Description: 500 mg Oat flour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihistamine
Description: Desloratidine 5 ml po od (0.5mg/ml = 2.5 mg) Ranitidine 5ml (15mg/ml=75 mg) po bid
Study: NCT01277692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2336805 10mg
Description: single dose once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2336805 30mg
Description: single dose once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2236805 100mg
Description: single dose once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2236805 200mg
Description: single dose once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2236805 10mg
Description: repeat dose once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2236805 dose to be determined up to 100mg
Description: repeat dose once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2236805 5mg
Description: single dose in HCV infected patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2236805 30mg
Description: single dose in HCV infected patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2236805 100mg
Description: single dose in HCV infected patients
Study: NCT03120468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate and N-Acetyl Cysteine
Description: Topiramate up to 200 mg/day and N-Acetyl Cysteine 600 mg twice a day for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate and Placebo
Description: Topiramate up to 200 mg/day and Placebo for 12 weeks
Study: NCT01689857

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scarclinic™ Thin
Description: Apply Scarclinic™ Thin on the scar and dispense 4 ea.for each participant for 3 month.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Scarclinic™ Normal
Description: Apply Scarclinic™ Normal on the scar and dispense 4 ea.for each participant for 3 month.
Study: NCT02639455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will exercise 4 days per week, 20 minutes per session for 5 weeks (a total of 400 minutes). Exercise will be independent (with the goal of 85% of max effort for at least 2 minutes each session) and consist of running, jumping jacks, sit ups, push ups, or burpees depending on the participant's comfort and skill.
Study: NCT04052815

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes prevention program culturally tailored
Description: Diabetes prevention Program (DPP) as specified by the CDC, physical activity prior to DPP sessions, motivational interviewing individual and in group. Culturally tailored nutrition tips and recipes.
Study: NCT00335140

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab is administered intravenously. The initial rate is 50 mg/hr for the first hour. If no toxicity is seen, the rate may be escalated gradually in 50 mg/hour increments at 30-minute intervals to a maximum of 300 mg/hr. If the first dose is well tolerated, the initial rate for subsequent dose is 100 mg/hr, increased gradually in 100 mg/hr increments at 30-minute intervals, not to exceed 400 mg/hr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 3 g/m2/day in 500 cc D5W IV over 2 hrs. x 2 doses 24hrs. apart, Weeks 11, 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 16mg (week 1) PO daily Weeks 1, 2, 3, 4, 5, 6 Taper by 4 mg/wk, weeks 2, 3, by 2 mg/wk week 4, 5, 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 25 mg PO/IV every 6 hrs. x 12 doses, Weeks 1, 3, 5, 7, 9 For patients with meningeal involvement additionally 10 mg PO every 12 hrs. x 8 doses, Weeks 2, 4, 6, 8, 10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 3.5 g/m2In 500 cc D5W + 25 mEq NaHCO3 IV over 2 hours, Weeks 1, 3, 5, 7, 9~For patients with meningeal involvement additionally:~12 mg Intrathecally, in preservative-free sterile .9NS Weeks 2, 4, 6, 8, 10 Via Ommaya or lumbar puncture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procarbazine
Description: 100 mg/m2 PO daily x 7 days Weeks 1, 5, 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m2 IV push, Weeks 1, 3, 5, 7, 9 2m2 (2.8 mg) dose cap
Study: NCT04849767

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire about socio-behavioral items and conditions of vulnerability. interview with female to male transgender person will be about life conditions, trajectory of the medical transition from female to male and actual medical following of the transition, migration trajectory and condition of HIV acquisition.
Study: NCT00919191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin gel
Description: Tretinoin gel 0.04% used once daily in a split-face model

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene and Benzoyl peroxide
Description: Adapalene .1% and Benzoyl peroxide 2.5%
Study: NCT03808142

Intervention type: OTHER
Intervention: myBETAapp
Description: Patients choosing to use the myBETAapp were required to insert the Mixject number from their prescribed Betaferon box, which serves as an opening key for the app. Obtaining a new Betaferon box and obtaining a new Mixject number was not interfere with the process of continuously allocating data to a single patient; each patient had a unique personal identifier in the database. All data recorded in the myBETAapp including demographic and injection-related data were stored in the database once the mobile device was connected to the internet.

Intervention type: OTHER
Intervention: PEAK
Description: Peak is an application that aims at helping its users to challenge their brains and keep them sharp.

Intervention type: DRUG
Intervention: Betaferon, BAY86-5046
Description: Injection

Intervention type: DEVICE
Intervention: BETACONNECT
Description: BETACONNECT automatically records and stores injection-related details including injection time, speed, and depth upon every injection.
Study: NCT00767429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fall risk detector
Description: fall risk detector: stumbles, specific fall related movements, falls
Study: NCT01753726

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragm stretching.
Description: A manual technique of diaphragm stretching during 7 minutes. The participants were situated in a seated position.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo.
Description: Disconnected ultrasound was used for the 7 min as sham treatment
Study: NCT03812029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonafexor
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonafexor
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonafexor
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonafexor
Description: Oral tablets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets
Study: NCT01128270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dichloroacetate environmental dose
Description: On day 6 they receive Dichloroacetate 2.5 ug/kg orally times 1 and have pharmacokinetics.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloral Hydrate environmental dose
Description: Study subjects are given 1.5 ug/kg of Chloral Hydrate for 5 nights and pharmacokinetics are done on night 1 and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloral Hydrate environmental dose
Description: Study subjects are given 1.5 ug/kg of Chloral Hydrate for 5 nights and pharmacokinetics are done on night 1 and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dichloroacetate therapeutic dose
Description: Subjects receive 25 mg/kg DCA on Day 6. Pharmacokinetics are done on nights 1 and nights 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloral Hydrate therapeutic dose
Description: Subject is given 25 mg/kg of Chloral Hydrate for five nights.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloral Hydrate therapeutic dose
Description: Subject is given 25 mg/kg of Chloral Hydrate for five nights.
Study: NCT01269151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis (Ranibizumab)
Description: Ranibizumab Short- and Log-term Effects on Retinal Function measured by Multifocal-ERG and Microperimetry
Study: NCT03738475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIMP-GLIA
Description: 8 mg/kg up to a maximum of 650 mg administered intravenously on days 1 and 8.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered intravenously on days 1 and 8.
Study: NCT05156151

Intervention type: OTHER
Group type: OTHER
Intervention: Relex-Smile
Study: NCT03157297

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MARVEL algorithm
Description: Software download into implanted Micra device
Study: NCT01923467

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Quit stop smoking program
Description: This online stop-smoking program is individually tailored to the participant's readiness to quit, smoking triggers, and many other characteristics. It has been scientifically proven to improve quit success.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patches 21 mg
Description: Eligible participants will receive a 2-week supply of Nicoderm CQ Step 1 patches to help them be successful in their quit attempt.
Study: NCT01539369

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy eating diet (Diet A) or healthy eating diet combined with advice to increase fibre intake (Diet B) to at least 25g/day
Description: Participants were randomly assigned to one of two parallel arms:~Diet A:healthy eating without extra advice to increase fibre intake or Diet B: healthy eating with extra advice to increase fibre intake to a minimum of 25g/d. Healthy eating advice was based on the British Heart Foundation booklet: Food Should Be Fun And Healthy. Participants following Diet A were encouraged to eat breakfast cereals and were provided with complementary cereals and snacks low in fibre. Participants following Diet B were encouraged to eat high fibre breakfast cereals and to incorporate wheat bran fibre in other meals. Complementary high fibre cereals and snacks were provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy eating diet (Diet A) or healthy eating diet combined with advice to increase fibre intake (Diet B) to at least 25g/day
Description: Participants were randomly assigned to one of two parallel arms:~Diet A:healthy eating without extra advice to increase fibre intake or Diet B: healthy eating with extra advice to increase fibre intake to a minimum of 25g/d. Healthy eating advice was based on the British Heart Foundation booklet: Food Should Be Fun And Healthy. Participants following Diet A were encouraged to eat breakfast cereals and were provided with complementary cereals and snacks low in fibre. Participants following Diet B were encouraged to eat high fibre breakfast cereals and to incorporate wheat bran fibre in other meals. Complementary high fibre cereals and snacks were provided.
Study: NCT03733353

Intervention type: DRUG
Group type: OTHER
Intervention: EDP1815
Description: EDP1815 is an orally administered monoclonal microbial

Intervention type: DRUG
Group type: OTHER
Intervention: EDP1815
Description: EDP1815 is an orally administered monoclonal microbial

Intervention type: DRUG
Group type: OTHER
Intervention: EDP1815
Description: EDP1815 is an orally administered monoclonal microbial

Intervention type: DRUG
Group type: OTHER
Intervention: EDP1815
Description: EDP1815 is an orally administered monoclonal microbial

Intervention type: DRUG
Group type: OTHER
Intervention: EDP1815
Description: EDP1815 is an orally administered monoclonal microbial
Study: NCT01329770

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E)
Description: * Vitamin E (D-alpha-Tocopherol) 10 mg/kg/day (with a maximum of 600mg/day)~* Vitamin C (L-Ascorbic Acid) 10 mg/kg/day (with a maximum of 800mg/day) For 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two daily dose of placebo, administered at breakfast and dinner for 12 weeks
Study: NCT03018275

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Roseomonas mucosa
Description: R mucosa grown in Hank's balanced salt solution. Bacteria is washed, quantitated spectrophotometrically, suspended in 10%-15% sucrose, and lyophilized.
Study: NCT02643433

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles-Rubella combined vaccine(MR)
Description: 0.5ml for each dose,be administered by single use syringe subcutaneously in the lower part of the deltoid area of lateral arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles-Rubella combined vaccine(MR)
Description: 0.5ml for each dose,be administered by single use syringe subcutaneously in the lower part of the deltoid area of lateral arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Japanese Encephalitis alive vaccine(JE)
Description: 0.5ml for each dose be administered by single use syringe subcutaneously in the lower part of the deltoid area of lateral arm.
Study: NCT03446092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness for health
Description: A course of mindfulness using the mindfulness for health programme.
Study: NCT03163719

Intervention type: DIAGNOSTIC_TEST
Intervention: CK and Lactate dosages
Description: A patient consulting the emergency department for suspected seizure will have an usual blood test at the admission in this context with notably ionogram, fasting glucose, venous gasometry. As the CHU purchased a venous and arterial gasometry reader for the emergency department, blood ionogram, Hb, lactates, HCO3-, pH are collected without delay. The Creatine kinase dosage will be collected in the usual way as a tube bottom. As recommended by the French Society of Neurology, a new sample will be collected at 4 hours of seizure for a dosage of Creatine kinase. The determination of the lactates will be based on a tube bottom.
Study: NCT01073163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine at 90 mg/m\^2 IV on Days 1 and 2 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab at 375 mg/m\^2 IV on Day 1 of a 28-day cycle.
Study: NCT00940888

Intervention type: DEVICE
Intervention: SJ4 connector and RV high voltage SJ4 lead
Description: Standard of care implantation of SJ4 device system
Study: NCT01228656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate + salicylic acid
Description: Dermatologic ointment applied once a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate
Description: Dermatologic ointment applied once a day
Study: NCT03977987

Intervention type: DRUG
Intervention: nucleos(t)ide analogue
Description: Pregnant women in this group agree to receive nucleos(t)ide analogue (tenofovir or telbivudine) daily from the 28 weeks of pregnancy to delivery.
Study: NCT01808937

Intervention type: OTHER
Intervention: Morphea
Study: NCT01275989

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Ear acupuncture
Study: NCT03733353

Intervention type: DRUG
Group type: OTHER
Intervention: EDP1815
Description: EDP1815 is an orally administered monoclonal microbial

Intervention type: DRUG
Group type: OTHER
Intervention: EDP1815
Description: EDP1815 is an orally administered monoclonal microbial

Intervention type: DRUG
Group type: OTHER
Intervention: EDP1815
Description: EDP1815 is an orally administered monoclonal microbial

Intervention type: DRUG
Group type: OTHER
Intervention: EDP1815
Description: EDP1815 is an orally administered monoclonal microbial

Intervention type: DRUG
Group type: OTHER
Intervention: EDP1815
Description: EDP1815 is an orally administered monoclonal microbial

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo oral capsule
Description: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo oral capsule
Description: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo oral capsule
Description: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo oral capsule
Description: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo oral capsule
Description: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo oral capsule
Description: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo oral capsule
Description: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo oral capsule
Description: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo oral capsule
Description: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo oral tablet
Description: Placebo
Study: NCT01275989

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ear acupuncture

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Ear acupuncture
Study: NCT04034212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Singing for Lung Health group attendance
Description: Singing for Lung Health is a group singing intervention designed for people with chronic lung diseases. Participants would attend weekly sessions lasting 1 hour.
Study: NCT02489448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: The investigational product is MEDI4736 which will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for intravenous (IV) administration.~Routine, standard of care chemotherapy will be given together with the investigational product and will include weekly nab-paclitaxel x12 treatments followed by every two-week doxorubicin, cyclophosphamide (ddAC) x 4 treatments.
Study: NCT04394156

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief cognitive intervention
Description: See the information provided in the experimental arm description.
Study: NCT01971567

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HIRREM

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: HIRREM
Study: NCT01384162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sNN0029
Description: ICV infusion
Study: NCT02224703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Study: NCT03834025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase 2 Condition 1
Description: Providers who enroll in the study and are assigned to this condition will be in this group. Other than the opportunity to participate in a learning collaborative, participants receive no compensation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase 2 Condition 2
Description: Providers who enroll in the study and are assigned to this condition will be in this group. In addition to the opportunity to participate in the learning collaborative, participants receive a reimbursement at 30% of the NC Medicaid rate for a patient visit.
Study: NCT02224703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Study: NCT03149042

Intervention type: DIAGNOSTIC_TEST
Intervention: CCTA
Description: Diagnostic Test